Business
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Company Announcement COPENHAGEN, Denmark; February 24, 2026 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 12,313 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the company or others. The shares are subscribed in cash at the following price per share of nominally DKK 1: 710 shares at DKK 1,147.50,239 shares at DKK 1,155.00,1,527 shares at DKK 1,161.00,1,183 shares at DKK 1,334.5
About this update from Genmab A/s
[{"type":"image","alt":"Genmab A/S","displaySize":"","headline":null,"caption":"Genmab A/S","className":"","disableSlideshowImg":false,"size":{"original":{"width":275,"height":85,"url":"https://media.zenfs.com/en/globenewswire.com/c0cd563151331363bc069dc3ced1531d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/3fXMaEmkURmdIw8oGLJV.g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEzMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/c0cd563151331363bc069dc3ced1531d","width":275,"height":85}},"lazy":false},{"type":"text","content":"Company Announcement","length":20,"tagName":"p"},{"type":"text","content":"COPENHAGEN, Denmark; February 24, 2026 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 12,313 shares as a consequence of the exercise of employee warrants.","length":170,"tagName":"p"},{"type":"text","content":"The increase is effected without any preemption rights for the existing shareholders of the company or others. The shares are subscribed in cash at the following price per share of nominally DKK 1:","length":197,"tagName":"p"},{"type":"text","content":"710 shares at DKK 1,147.50,239 shares at DKK 1,155.00,1,527 shares at DKK 1,161.00,1,183 shares at DKK 1,334.50,5,391 shares at DKK 1,362.50, and3,263 shares at DKK 1,615.00.","length":179,"tagName":"p"},{"type":"text","content":"Proceeds to the company are approximately DKK 17.1 million. The increase corresponds to approximately 0.02% of the company's share capital.","length":143,"tagName":"p"},{"type":"text","content":"The new shares are ordinary shares without any special rights and are freely transferable negotiable instruments. The new shares give rights to dividends and other rights in relation to the company as of subscription. The new shares will be listed on Nasdaq Copenhagen after registration with the Danish Business Authority. The capital increase is expected to be finalized shortly.","length":381,"tagName":"p"},{"type":"text","content":"Pursuant to section 32 of the Danish Capital Markets Act No. 1493 of November 18, 2025, it is hereby announced, that the total nominal value of Genmab A/S' share capital after the capital increase is DKK 64,250,721 which is made up of 64,250,721 shares of a nominal value of DKK 1 each, corresponding to 64,250,721 votes.","length":330,"tagName":"p"},{"type":"text","content":"About Genmab Genmab is an international biotechno...